



HPV Testing

Pathlab are transitioning to the BD Onclarity HPV test.

This test shows similar performance in detecting high risk HPV and identifies the same 14 “high risk” strains as the Roche Cobas test.

The new test does provide more information as to the specific strains of HPV types beyond identifying HPV-16 and HPV-18 individually with the other 12 strains grouped as “Other”.

Following the transition HPV results will have additional type information presented depending on the specific strains detected.

In addition to specifically identifying HPV-16 and HPV-18 the following will also be individually identifiable (31, 45, 51, 52), the others will be reported as being a member of a group (33/58), (35/39/68), and (56/59/66).

This additional information does not affect clinical decision making in either the current programme or the draft protocols for primary HPV screening. We do however feel that this information can be useful when advising individual patients.

The transition is expected to be complete by December 2017.

**Please ensure all members of your institution
receive a copy of this clinical update.**

Dr Richard Massey
Pathologist
(07) 578 7073

Murray Robinson
Lead of Specialty, Microbiology & Molecular Diagnostics